LEADER 02247nam 2200517 a 450 001 9910781080003321 005 20230616235541.0 010 $a0-7022-3754-X 035 $a(CKB)2550000000006547 035 $a(EBL)480356 035 $a(OCoLC)609854776 035 $a(SSID)ssj0000362344 035 $a(PQKBManifestationID)12137752 035 $a(PQKBTitleCode)TC0000362344 035 $a(PQKBWorkID)10362587 035 $a(PQKB)11041548 035 $a(MiAaPQ)EBC480356 035 $a(Au-PeEL)EBL480356 035 $a(CaPaEBR)ebr10366893 035 $a(CaONFJC)MIL534992 035 $a(EXLCZ)992550000000006547 100 $a20060629d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aLatecomers$b[electronic resource] /$fJaya Savige 210 $aSt. Lucia, Queensland $cUniversity of Queensland Press ;$aPortland, Or. $cDistributed in the USA by International Specialized Books Services$d2005 215 $a1 online resource (97 p.) 300 $aDescription based upon print version of record. 311 $a1-306-03741-7 311 $a0-7022-3519-9 327 $aCover; About the Author; Acknowledgments; Dedication; Contents; Epigraph; I The Unofficial History Pavilion; II Skirmish Point; III As Though We Were Never Here; Notes 330 $aWinner of the prestigious Arts Queensland Thomas Shapcott Poetry Prize, Jaya Savige's Latecomers is a first collection of poems by one of Australia's most exciting young poets. Lively, playful, and always intelligent, Savige's poems show an awareness of place, of the inescapability of history, and a personal commitment to the precision of language.""The poems in Latecomers go beyond what we take for granted these days in a first collection: refinement of language and cadence, allusiveness, wit. Moving easily through abstract wonders and the streets of the inne 606 $aShort stories, Australian 615 0$aShort stories, Australian. 676 $aA821.4 700 $aSavige$b Jaya$f1978-$01561376 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910781080003321 996 $aLatecomers$93828041 997 $aUNINA LEADER 04451nam 22005415 450 001 9910383831803321 005 20250610110555.0 010 $a3-030-32482-6 024 7 $a10.1007/978-3-030-32482-7 035 $a(CKB)4100000010770859 035 $a(DE-He213)978-3-030-32482-7 035 $a(MiAaPQ)EBC6152185 035 $a(PPN)243226055 035 $a(MiAaPQ)EBC29093031 035 $a(EXLCZ)994100000010770859 100 $a20200330d2020 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHodgkin Lymphoma $eA Comprehensive Overview /$fedited by Andreas Engert, Anas Younes 205 $a3rd ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (IX, 509 p. 102 illus., 83 illus. in color.) 225 1 $aHematologic Malignancies,$x2197-9766 311 08$a3-030-32481-8 327 $aPart I: Epidemiology and Pathogenesis -- Epidemiology of Hodgkin Lymphoma -- The role of viruses in the genesis of Hodgkin Lymphoma -- Pathology and molecular pathology of Hodgkin Lymphoma -- Microenvironment, cross-talk and immune escape mechanisms.-What will we learn from Genomics and Proteomics in Hodgkin Lymphoma? -- Part II: Diagnosis and first-line treatment -- Clinical evaluation -- Functional imaging in Hodgkin Lymphoma -- Prognostic factors. - Principles of Radiation Therapy for Hodgkin Lymphoma -- Principles of chemotherapy in Hodgkin Lymphoma -- Treatment of early favorable Hodgkin Lymphoma -- Treatment of early unfavorable Hodgkin Lymphoma -- Treatment of advanced-stage Hodgkin Lymphoma -- Optimizing Decision Making in HL -- Part III: Special clinical situations -- Paediatric/adolescent Hodgkin Lymphoma -- The management of elderly patients with Hodgkin Lymphoma -- Nodular Lymphocyte-Predominant Hodgkin Lymphoma -- The management of Hodgkin Lymphoma during pregnancy -- The management of HIV-Hodgkin Lymphoma -- Part IV: Relapsed and refractory disease -- Relapsed and refractory Hodgkin Lymphoma -- Allogeneic transplantation for relapsed Hodgkin Lymphoma -- Targeting CD30 in Patients with Hodgkin Lymphoma -- Hodgkin Lymphoma and PD-1 blockade -- Other new agents for Hodgkin Lymphoma -- Part V: Survivorship -- Quality of Life in Hodgkin lymphoma -- Second malignancy risk after treatment of Hodgkin Lymphoma -- Cardiovascular and pulmonary late effects -- Gonadal dysfunction and fertility preservation in Hodgkin Lymphoma patients -- Fatigue. 330 $aThis book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma. 410 0$aHematologic Malignancies,$x2197-9766 606 $aHematology 606 $aOncology 606 $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 615 0$aHematology. 615 0$aOncology. 615 14$aHematology. 615 24$aOncology. 676 $a616.42 702 $aEngert$b Andreas$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aYounes$b Anas$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910383831803321 996 $aHodgkin Lymphoma$91763320 997 $aUNINA